Compensated Awareness Post View
Disclaimer
ZENO Sensing Growth in 2 Vital Detection Markets
In modern medicine, life and death can be measured in mere days or weeks. Early detection of various cancers and illnesses can often mean a huge difference in survival rates of patients. You may often hear some doctors say that “if you had come in to see me a week later, it might have been too late,” or “if you had come in two weeks sooner, we would have never seen that growth.”
Medical technology has been continuing to evolve to find ways for certain cancers and illnesses to be spotted before a patient enters a doctor’s office for a routine exam. Zenosense, Inc. (OTCQB: ZENO) is one of the one-and-coming early-detection players, and continues to progress toward using exhaled breath as a tool for detection of possible infection or disease.
Zenosense is currently working a couple of devices that will help people use exhaled breath to indicate the presence of MRSA or lung cancer. Research as shown evidence of what are called “markers” that could be found in a person’s exhalations that may suggest the presence of either one of these disorders – potentially sooner than could be found in regular hospital tests. The company recently announced plans to develop a prototype electronic nose device that would be designed to detect lung-cancer markers. The prototype would soon be subject to a clinical trial.
With lung cancer being one of the more common forms of cancer, and with MRSA being very dangerous and deadly due to its antibiotic resistance and propagating ability, any company that is focusing on early detection of either of these illnesses is a company to which one should pay attention. If Zenosense can successfully develop a prototype early-detection device for either or both of these conditions, medicine could be disrupted in ways from which it may never recover. But that can be a strong lead toward establishing better health among patients and fewer hospital visits.
For more information, visit www.zenosense.net
AI
